Vyzkoušejte nový nástroj s podporou AI
Summon Research Assistant
BETA
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
Kosoglou, Teddy, Reyderman, Larisa, Tiessen, Renger G., van Vliet, André A., Fales, Robert R., Keller, Robert, Yang, Bo, Cutler, David L.
Published in European journal of clinical pharmacology (01.03.2012)
Published in European journal of clinical pharmacology (01.03.2012)
Get full text
Journal Article
Abstract 10315: The Effect of Protease-Activated Receptor-1 Inhibition With Vorapaxar in Post-mi and Nstemi Patients on Selected Biomarkers Reflecting Endothelial Function
Nilsen, Dennis W, Røysland, Michelle, Ueland, Thor, Aukrust, Pal, Michelsen, Annika E, Staines, Harry, Barvik, Ståle, Kontny, Frederic, Nordrehaug, Jan Erik, Bonarjee, Vernon V
Published in Circulation (New York, N.Y.) (08.11.2022)
Published in Circulation (New York, N.Y.) (08.11.2022)
Get full text
Journal Article
Abstract 10315: The Effect of Protease-Activated Receptor-1 Inhibition With Vorapaxar in Post-mi and Nstemi Patients on Selected Biomarkers Reflecting Endothelial Function
Nilsen, Dennis W, Røysland, Michelle, Ueland, Thor, Aukrust, Pal, Michelsen, Annika E, Staines, Harry, Barvik, Ståle, Kontny, Frederic, Nordrehaug, Jan Erik, Bonarjee, Vernon V
Published in Circulation (New York, N.Y.) (08.11.2022)
Published in Circulation (New York, N.Y.) (08.11.2022)
Get full text
Journal Article
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
Kosoglou, Teddy, Reyderman, Larisa, Kasserra, Claudia, Jennings, Lisa K., Young, Sophia, Xuan, Fengjuan, Pei, Jinglan, Maxwell, Stephen E., Schiller, James, Meehan, Alan G., Cutler, David L.
Published in European journal of clinical pharmacology (01.03.2012)
Published in European journal of clinical pharmacology (01.03.2012)
Get full text
Journal Article
No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
Anderson, Matt S., Kosoglou, Teddy, Statkevich, Paul, Li, Jing, Rotonda, Jennifer, Meehan, Alan G., Cutler, David L.
Published in Clinical pharmacology in drug development (01.02.2018)
Published in Clinical pharmacology in drug development (01.02.2018)
Get full text
Journal Article
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
Kosoglou, Teddy, Kraft, Walter K., Kumar, Bharath, Statkevich, Paul, Xuan, Fengjuan, Ma, Lei, Jennings, Lisa K., Schiller, James E., Langdon, Ronald B., Cutler, David L.
Published in European journal of clinical pharmacology (01.07.2012)
Published in European journal of clinical pharmacology (01.07.2012)
Get full text
Journal Article
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
Kraft, WK, Gilmartin, JH, Chappell, DL, Gheyas, F, Walker, BM, Nagalla, S, Naik, UP, Horrow, JC, Wrishko, RE, Zhang, S, Anderson, MS
Published in Clinical and translational science (01.08.2016)
Published in Clinical and translational science (01.08.2016)
Get full text
Journal Article
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development
Franchi, Francesco, Rollini, Fabiana, Park, Yongwhi, Angiolillo, Dominick J
Published in Future cardiology (01.09.2015)
Published in Future cardiology (01.09.2015)
Get full text
Journal Article
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin
Kosoglou, Teddy, Zhu, Yali, Xuan, Fengjuan, Black, Laura, Johnson-Levonas, Amy O., Martinho, Monika, Statkevich, Paul, Cutler, David L.
Published in European journal of clinical pharmacology (01.11.2012)
Published in European journal of clinical pharmacology (01.11.2012)
Get full text
Journal Article
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
Angiolillo, Dominick, Cho, Jung Rae, Rollini, Fabiana, Franchi, Francesco, Ferrante, Elisabetta
Published in Vascular health and risk management (01.01.2014)
Published in Vascular health and risk management (01.01.2014)
Get full text
Journal Article
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone
Kosoglou, Teddy, Kumar, Bharath, Statkevich, Paul, Schiller, James E., Kantesaria, Bhavna, Hanson, Mary E., Sisk, Christine McCrary, Cutler, David L.
Published in Clinical pharmacology in drug development (01.01.2015)
Published in Clinical pharmacology in drug development (01.01.2015)
Get full text
Journal Article
The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease
Nilsen, Dennis W. T., Røysland, Michelle, Ueland, Thor, Aukrust, Pål, Michelsen, Annika E., Staines, Harry, Barvik, Ståle, Kontny, Frederic, Nordrehaug, Jan Erik, Bonarjee, Vernon V. S.
Published in Thrombosis and haemostasis (01.05.2023)
Published in Thrombosis and haemostasis (01.05.2023)
Get full text
Journal Article
Operations Committee provides additional information to investigators in study of Merck's vorapaxar
Published in M2 Pharma
(20.01.2011)
Get full text
Newsletter
Merck Says Additional Information Provided to Investigators in Clinical Study of Vorapaxar
Published in Business Wire
(19.01.2011)
Get full text
Newsletter